Veronica Galvan
Led mouse studies showing that rapamycin prevents Alzheimer's-like memory loss and amyloid build-up, and improves learning in normally ageing mice
Professor & Donald W. Reynolds Endowed Chair, Univ. of Oklahoma HSC (since 2021); Editor-in-Chief, GeroScience · UT Health San Antonio, Barshop Institute (until 2021) · postdoc, Buck Institute (Dale Bredesen) · PhD virology, Univ. of Chicago (Bernard Roizman, 1999) · MS, Univ. of Buenos Aires (1994)
Galvan Lab, University of Oklahoma Health Sciences Center (Oklahoma City, Oklahoma, USA) ↗ Lab lineagetrained under Dale E. Bredesen →
Portrait: University of Oklahoma Health Sciences Center
Senior author on SPI2010 (rapamycin prevents Alzheimer's-model cognitive decline, lowers amyloid-beta) and HAL2012 (chronic rapamycin enhances cognition across normal aging, no cost to the aging brain).
Work done with Barshop Institute collaborators Richardson and Strong (both already in the Atlas). Seeded her career-long focus on mTOR as a druggable node between brain aging and Alzheimer's; co-author on a 2025 pilot Phase 1 rapamycin/Alzheimer's clinical trial.
Moved to OU Health Sciences Center in 2021; directs the Oklahoma Nathan Shock Center on Aging; past President, American Aging Association (2021–2022); Editor-in-Chief, GeroScience (since 2021).
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2010 | A | Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease SPI2010 Senior author: long-term rapamycin prevents memory deficits and lowers amyloid-beta, tracking with increased autophagy. |
| 2012 | A | Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. HAL2012 Senior author: a lifespan-extending rapamycin dose enhances cognition and reduces anxiety/depression-like behavior. |
Co-authors in the Atlas 7
People with a profile here who share at least one study with Veronica Galvan.
ShowHide
- Arlan Richardson 2 shared studies Studies how rapamycin slows ageing in mice, including the broad changes it causes in the liver, and co-authored early studies showing that rapamycin protects memory in Alzheimer's-model mice
- Natalia Podlutskaya 2 shared studies Contributed, at the Barshop Institute in San Antonio, to mouse studies showing that rapamycin prevents Alzheimer's-like memory loss and improves cognition in normal ageing
- Randy Strong 2 shared studies Leads the San Antonio site of the NIA Interventions Testing Program, which tests each compound in parallel at three sites under one shared protocol. He first-authored the program's reports on resveratrol and other supplements (2012) and on rapamycin combined with acarbose (2022)
- Jayanta Debnath Physician-scientist who studies how autophagy - the cell's self-digestion system - keeps epithelial tissue healthy and how tumours hijack it
- Jonathan J. Halloran First author of a 2012 mouse study showing that lifelong rapamycin does not cost the brain anything and even protects learning and memory with age; long-time member of Veronica Galvan's aging and Alzheimer's research group in San Antonio
- Patricia Spilman Neuroscientist who showed, with Veronica Galvan, that long-term rapamycin prevents memory loss in an Alzheimer's mouse model, and who later worked with Dale Bredesen on Alzheimer's drug discovery
- Stacy A. Hussong Studies how mTOR damages the brain's blood vessels, and how blocking it restores blood flow, the blood-brain barrier and memory in aging and Alzheimer's models
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.